Dermsquared - The leading solutions platform for dermatology professionals to elevate patient care

FC26 Continuity Experience

Atopic dermatitis beyond the meeting

Video

Which findings from the cosibelimab clinical data have had the greatest influence on how you think about its role in advanced cSCC?

Feat. Brent Moody, MD, FAAD, FACP

Podcast

Greatest Hits of Derms and Conditions 2025

Feat. James Q. Del Rosso, DO

Case Study

Remibrutinib for Chronic Spontaneous Urticaria: Rapid Symptom Control With an Oral Treatment Option

By Dermsquared Editorial Team

CME

DermInsider - Session 6: EB Evolved: Addressing Unmet Needs in Pediatric Epidermolysis Bullosa with Novel Therapies

With Elizabeth (Lisa) Swanson, MD

Innovation Corner

Chronic Inducible Urticaria

Move beyond identifying what sets symptoms off toward a more complete picture of burden, treatment expectations, shared decision-making, and long-term disease control.

Think Beyond What is Active

Take a closer look at how CLE is recognized and assesses what extends beyond active inflammation

An Interactive Learning Journey

Explore the science, practical application, and evolving role of AhR agonism

Act Before HS Leaves Its Mark

In HS, what appears controlled in the moment may still be moving toward lasting structural change, raising an increasingly important question of when treatment should shift toward altering disease trajectory.

A Type 2 Inflammation Experience

Through expert perspectives and embedded knowledge checks, you’ll recognizing where these conditions connect can sharpen how you understand each one.

Expanding Nonsteroidal Options

Explore how an expanding range of nonsteroidal options may change topical strategy across chronic inflammatory skin disease.